Loading the section…

STAA: financial statements from SEC — TradeAlmanac

STAA

STAAR Surgical Company: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	239M	314M
Cost of revenue	57M	74M
Gross profit	182M	240M
Research and development	40M	45M
Selling, general and administrative	274M	252M
Operating income	−92M	−13M
Pre-tax income	−82M	−9M
Income tax	−2M	11M
Net income	−80M	−20M
Earnings per share	−1.62	−0.41
Earnings per share, diluted	−1.62	−0.41
Weighted average shares	50M	49M
Weighted average shares, diluted	50M	49M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	132M	153M	176M	167M	173M	144M	164M	193M
Short-term investments	32M	34M	17M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	−34M	16M
Depreciation and amortisation	8M	7M
Share-based compensation	31M	27M
Capital expenditure	6M	23M
Investing cash flow	46M	−59M
Share buybacks	6M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator